Biotech Day In Review: Agilent Buys Stratagene For $245.5 Million [View article]
SEEKING THIRD PARTY OPINION FROM ASTUTE INVESTOR, WHO HAS THE KNOWLEDGE,COURAGE AND GUTS TO EITHER CONCUR OR DISAGREE WITH THE FOLLOWING: IT IS IN MY OPINION THAT INVESTING IN 'NSTK' NOW IS NOT THE BEST THING TO DO WITH YOUR MONEY. TWO YEARS AWAY FROM APPROVAL,IF APPROVED,POOR RATINGS,POOR FUNDAMENTALS,POOR MANAGEMENTS ABILITY TO TURN COMPANY AROUND, POOR EARNING REPORTS SCHEDULED FOR MAY REGARDING MARCH 2007 AND THE SAME FOR DECEMBER 2007. HAVING SAID THAT, THERE IS NO MOMENTUM, AND NO REASON FOR THE STOCK PRICE TO APPRECIATE IN THE COMING MONTHS AHEAD. SO ISN'T WISE TO INVEST IN OTHER POTENTIAL BIOTECH STOCKS IN THE MEANTIME? AM I RIGHT OR WRONG? JT
Biotech Day In Review: Agilent Buys Stratagene For $245.5 Million [View article]
TWO YEARS AWAY FROM APPROVAL,IF APPROVED,POOR RATINGS,POOR FUNDAMENTALS,POOR MANAGEMENTS ABILITY TO TURN COMPANY AROUND, POOR EARNING REPORTS SCHEDULED FOR MAY REGARDING MARCH 2007 AND THE SAME FOR DECEMBER 2007. HAVING SAID THAT, THERE IS NO MOMENTUM, AND NO REASON FOR THE STOCK PRICE TO APPRECIATE IN THE COMING MONTHS AHEAD. SO ISN'T WISE TO INVEST IN OTHER POTENTIAL BIOTECH STOCKS IN THE MEANTIME? AM I RIGHT OR WRONG?
JT